Knowledge of MYCN amplification status alone may not be sufficient to determine those patients most likely to respond to antifolate therapy, and assessment of any potential clinical application of these findings will also have to consider the limitations of methotrexate toxicity and methotrexate availability in the tumor. This evidence concerns the gene MYCN and neoplasm.